30 reports

  • for Licensing Deals Valued Above $100m
  • Strategic Consolidations

Phase II Small molecule LP-## LEO Pharma A/ S Accolade Pharmaceuticals LLC Phase II Undisclosed Undisclosed Cysteinyl Leukotriene Receptor ## (Cysteinyl Leukotriene D## Receptor or G Protein Coupled R Zafi-## Phase II Small molecule t HG## HMTMF## CYSLTR##) AQ-##

  • Dermatological Condition
  • Dermatology
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Clear Cell Pipeline by Companies
  • IV. RCC Drug Pipeline by Companies

RCC Market Patent Trend by Top Inventors Merck ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Pfizer ## ## ## ## ## ## ## ## ## ## ## ## ## ## Roche ## ## ## ## ## ## ## ## ## ## ## ## ## ## NIH ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Genentech ## ## ## ## ## ## ## ## ##

  • Cancer
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • Incyte Corporation
  • IDO inhibitors pipeline candidates by companies
  • ACTIVE COMPANIES: CATEGORY AND PARAMETERS

You can easily book an appointment with one online.

  • Antiviral
  • Pharmaceutical
  • Therapy
  • United States
  • Incyte Corporation
  • Source: Ariad Pharmaceuticals, Incyte Corp, CancerReasearchAnalytics.com
  • Source: Ariad Pharmaceuticals, Incyte Corp, CancerResearchAnalytics.com

“Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the most controversial drug in recent times. Iclusig is the first and only drug approved for Ariad Pharmaceuticals, classified into kinase inhibitor class and falls under targeted therapy group of drugs....

  • Pharmaceutical
  • North America
  • ARIAD Pharmaceuticals, Inc.
  • Incyte Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • OTHER DRUGS IN DEVELOPMENT FOR MF, 2016
  • 9.2 COMMERCIAL BENCHMARK OF KEY PIPELINE DRUGS

MEI Pharma is collaborating with the M. D.

  • Pharmaceutical
  • Japan
  • United States
  • Forecast
  • Incyte Corporation

REFERENCE CODE: SMDB## PUBLISHED: APRIL 2016 Social Media Advertising Spend in China, 2016 Databook List of Figures List of Tables ##.

  • Advertising
  • Computer
  • Pharmaceutical
  • Social Network
  • Tencent Holdings Ltd

Brands pay for space on one or more of the online company' s pages to display a static or linked banner or logo.

  • Advertising
  • Computer
  • Online Advertising
  • Pharmaceutical
  • Tencent Holdings Ltd
  • JIANGSU HENGRUI MEDICINE

JINGHUA PHARMACEUTICAL CO ID No.

  • Pharmaceutical
  • Therapy
  • AstraZeneca PLC
  • Aurigene Discovery Technologies Limited
  • Incyte Corporation
  • 2. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
  • 2. EXECUTIVE SUMMARY

TWITTER IS ONE OF THE MOST POPULAR PLATFORMS WHEREIN THOUSANDS OF INDIVIDUALS FOLLOW SEVERAL PHARMACEUTICAL COMPANIES.

  • Arthritis
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Incyte Corp, Pharmaceuticals & Healthcare, Deal Details
  • Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Summary Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics.The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Incyte Corporation
  • ID No. Name

Innate Pharma PR Oct ##, 2016 - The study enrolled ## patients.

  • Cancer Immunotherapy
  • Pharmaceutical
  • Therapy
  • AstraZeneca PLC
  • Incyte Corporation
  • 01. Executive Summary
  • 18. Vendor Landscape

It is ranked as one of the top ## companies in the Pharmaceutical industry.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • Alexion Pharmaceuticals, Inc.
  • Incyte Corporation
  • SMALL MOLECULES COMPETITIVE LANDSCAPE
  • SMALL MOLECULES

Phase ## OX## antagonis t Inflamation (Atopic Dermatitis) Glenmark pharma XOMA TAB## GBR ## MONOCLONAL ANTIBODIES Monalizumab +Durvalumab MOLECULE PHASE MOA THERAPEUTIC AREA (INDICATION) COMPANY Phase ## Phase ## Lirilumab+Ni Phase ## volumab Lirilumab+Ni volumab Pha

  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Agenus Inc.
  • Incyte Corporation

REFERENCE CODE: SMDB## PUBLISHED: APRIL 2015 Social Media Advertising Spend in China, 2015 Databook List of Figures List of Tables ##.

  • Advertising
  • Marketing
  • Pharmaceutical
  • Social Network
  • Tencent Holdings Ltd

Pancreatic cancer

4546 5000 3864

Pharmaceuticals Policy and Law, ##, ##-##.

  • Pharmaceutical
  • European Union
  • Japan
  • United States
  • Incyte Corporation
  • 8.2 LATE-STAGE DRUGS IN CLINICAL DEVELOPMENT
  • PRODUCT PROFILE - INCB40093 (+INCB39110)

PHARMA JAPAN WEB.

  • Pharmaceutical
  • United States
  • Demand
  • Market Size
  • Incyte Corporation

Digital Advertising Spend in China, 2015 Databook REFERENCE CODE: DSDB## PUBLISHED: APRIL 2015 LIST OF FIGURES LIST OF TABLES ##.

  • Advertising
  • Computer
  • Online Advertising
  • Pharmaceutical
  • Tencent Holdings Ltd
  • IMMUNE CHECKPOINT INHIBITORS: DISTRIBUTION BY DRUG DEVELOPERS
  • NOVEL IMMUNE CHECKPOINT INHIBITORS PIPELINE: DISTRIBUTION BY COMPANIES

Roche NA NA AstraZeneca ## I NCT## Recruiting Kyowa Hakko Kirin Pharma, Inc.

  • Cancer Immunotherapy
  • Pharmaceutical
  • Therapy
  • Market Size
  • Incyte Corporation
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..3), H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..1), H1 2018

Celon Pharma SA (Celon Pharma) is an integrated pharmaceutical company which carries out research and develops new medicines.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • IONIS PHARMACEUTICALS INC
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES

Thalassemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2018, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited...

  • Blood Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Incyte Corporation
  • RUXOLITINIB PHOSPHATE - DRUG PROFILE

PIPELINE BY NOVARTIS AG, H## 2017 NS PHARMA INC NS Pharma Inc (NS Pharma), a subsidiary of Nippon Shinyaku Co Ltd, is a pharmaceutical company that develops drugs for muscular disorders.

  • Arthritis
  • Pharmaceutical
  • Research And Development
  • Therapy
  • Incyte Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES

Grade ## AEs potentially related to study medication included thrombocytopenia (##), neutropenia (##), renal tumor (##), asthenia (##), viral infection (##), and atrial flutter (##).

  • Blood Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Incyte Corporation
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES
  • RUXOLITINIB PHOSPHATE - DRUG PROFILE

Grade ## AEs potentially related to study medication included thrombocytopenia (##), neutropenia (##), renal tumor (##), asthenia (##), viral infection (##), and atrial flutter (##).

  • Blood Disease
  • Pathology
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
  • CTP-543 - DRUG PROFILE

PIPELINE BY ACLARIS THERAPEUTICS INC, H## 2017 ASTELLAS PHARMA INC Astellas Pharma Inc (Astellas) is one of the leading global pharmaceutical companies, which focuses on the research, development, manufacture and commercialization of a wide range of

  • Arthritis
  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • HAN WHA PHARMA CO LTD
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018 Summary Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2018,...

  • Arthritis
  • Dermatological Condition
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Mic ro env ir on ment

The company is a specialist in hit-to-lead optimization Redx Pharma Solid tumors Res Small molecule (NCE) IDO & TDO INHIBITORS: NOVEL TDO INHIBITORS - ##/ ## ## ## TDO inhibitor (IOmet) Tryptophan (##, ##) dioxygenase (TDO) inhibitor Small molecule Merck (acquired IOmet

  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • CORPORATE VENTURING - DEAL REPORTS

Target Acquirer ## Acquirer ## Tesla Motors, Inc.

  • Pharmaceutical
  • China
  • Company
  • M&A
  • Tencent Holdings Ltd
  • CORPORATE VENTURING - DEAL REPORTS

Target Acquirer ## Acquirer ## Tesla Motors, Inc.

  • Pharmaceutical
  • China
  • Company
  • M&A
  • Tencent Holdings Ltd
  • Jul 05, 2012
  • Incyte Corporation Overview

In collaboration with Incyte, Novartis International Pharmaceutical Ltd.

  • Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Incyte Corporation
  • CORPORATE VENTURING - DEAL REPORTS

Target Acquirer ## Acquirer ## Tesla Motors, Inc.

  • Pharmaceutical
  • China
  • Company
  • M&A
  • Tencent Holdings Ltd